Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market.

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

Uncertainty about pharmaceutical tariffs continues to loom over the pharmaceutical industry, with some companies committing ...

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its ...

In 2023, the company booked $45.8 billion in revenue. CFO Aradhana Sarin said she is now focused on the execution of launching the products after the data reveal.

Aradhana Sarin, MD, who is currently Alexion’s executive vice president and CFO, will replace Marc Dunoyer as AstraZeneca’s CFO.